Items where authors include "Chehadah, F"

Proceedings Paper

Hulme, C, Hall, P, Shinkins, B orcid.org/0000-0001-5350-1018 et al. (5 more authors) (2018) PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results. In: Annals of Oncology. ESMO 2018, 19-23 Oct 2018, Munich, Germany. Oxford University Press .